Sinopharm Shantou Jinshi Pharmaceutical Co., Ltd.

This study aims to study the pharmacokinetic characteristics of a single fasting oral dose of norfloxacin capsules (0.1 g) developed and produced by Shantou Jinshi Pharmaceutical Co., Ltd. of Sinopharm Group, and to use norfloxacin tablets (BACCIDAL®, 0.1 g) certified by Kyorin Pharmaceutical Co., Ltd. as the reference preparation. The pharmacokinetic parameters of the two preparations are compared to evaluate the human bioequivalence of the two preparations and to observe the safety of the test preparation and the reference preparation in healthy participants.

Primary objective: To evaluate the pharmacokinetic parameters of ambroxol hydrochloride tablets (30 mg) produced by Shantou Jinshi Pharmaceutical Co., Ltd. of Sinopharm Group and ambroxol hydrochloride tablets (SURBRONC®, 30 mg) certified by OPELLA HEALTHCARE FRANCE SAS using a single-center, randomized, open, single-dose, two-preparation, two-period, self-crossover design, and to evaluate the bioequivalence of the test preparation and the reference preparation under fasting and fed conditions. Secondary objective: To observe the safety of the test preparation and the reference preparation when taken orally in healthy subjects.

Main purpose: This study aims to study the pharmacokinetic characteristics of cefaclor granules (0.125 g/bag) produced by Shantou Jinshi Pharmaceutical Co., Ltd. of Sinopharm Group after oral administration on an empty stomach and after meals, and to compare the pharmacokinetic parameters of the two preparations and evaluate the bioequivalence of the two preparations in humans using cefaclor dry suspension (Cefaclor®, 0.125 g/bag) produced by Suzhou Xikro Pharmaceutical Co., Ltd. as the reference preparation. Secondary purpose: To observe the safety of oral administration of the test preparation cefaclor granules (0.125 g/bag) and the reference preparation cefaclor dry suspension (Cefaclor®, 0.125 g/bag) in healthy subjects.